Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) Director Julie A. Cullivan sold 993 shares of the business's stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the completion of the sale, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Axon Enterprise Trading Down 1.1 %
Shares of AXON opened at $278.53 on Tuesday. Axon Enterprise, Inc. has a 1 year low of $175.37 and a 1 year high of $329.87. The company has a 50 day simple moving average of $302.57 and a two-hundred day simple moving average of $277.46. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55. The firm has a market cap of $21.02 billion, a P/E ratio of 81.44 and a beta of 0.91.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The company had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. During the same period in the previous year, the firm posted $0.51 EPS. Axon Enterprise's revenue for the quarter was up 34.3% compared to the same quarter last year. On average, equities analysts expect that Axon Enterprise, Inc. will post 2.35 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Axon Enterprise
Are You Positioned For The New Energy Goldrush?
From Wealthpin Pro | Ad
Open AI’s Sam Altman recently helped this company raise $577 million in funding…What’s more is, It has already inked deals with the Department of Energy.
Click here to get all the information about it.
A number of hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. raised its holdings in shares of Axon Enterprise by 15.5% during the 3rd quarter. Victory Capital Management Inc. now owns 67,280 shares of the biotechnology company's stock worth $13,388,000 after acquiring an additional 9,045 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Axon Enterprise in the 3rd quarter worth $132,000. Kestra Private Wealth Services LLC grew its stake in shares of Axon Enterprise by 9.5% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 2,315 shares of the biotechnology company's stock worth $461,000 after buying an additional 200 shares in the last quarter. New York Life Investment Management LLC increased its holdings in shares of Axon Enterprise by 0.8% in the 3rd quarter. New York Life Investment Management LLC now owns 10,102 shares of the biotechnology company's stock worth $2,010,000 after buying an additional 78 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its position in shares of Axon Enterprise by 159.7% during the 3rd quarter. Avantax Advisory Services Inc. now owns 4,971 shares of the biotechnology company's stock valued at $989,000 after buying an additional 3,057 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
AXON has been the topic of several analyst reports. William Blair reissued an "outperform" rating on shares of Axon Enterprise in a report on Wednesday, April 24th. Barclays increased their price objective on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an "overweight" rating in a research report on Wednesday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $400.00 target price on shares of Axon Enterprise in a report on Tuesday, May 7th. The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $297.00 to $339.00 and gave the company a "buy" rating in a report on Wednesday, February 28th. Finally, TheStreet lowered shares of Axon Enterprise from a "b" rating to a "c+" rating in a report on Tuesday, February 27th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $335.27.
View Our Latest Stock Report on Axon Enterprise
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
- Five stocks we like better than Axon Enterprise
- Breakout Stocks: What They Are and How to Identify Them
- Why Smartsheet Stock is an Undervalued Gem of an Investment
- Technology Stocks Explained: Here's What to Know About Tech
- The Most Upgraded Stocks After the Q1 Earnings Season
- How to Capture the Benefits of Dividend Increases
- What Is Risk Tolerance & Why Is It Important?
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected].
Insider Buying or Selling at Axon Enterprise?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Axon Enterprise and related companies.
More From MarketBeat
